Abstract |
Tumor necrosis factor alpha (TNF-α) is a cytokine with pleiotropic actions that can be present both as a transmembrane protein and soluble cytokine (sTNF). Both ligands interact with two different receptors, TNFR1 and TNFR2, which mediate their biological effects. TNF-α is involved in the pathogenesis of multiple sclerosis (MS), however, administration of anti-TNF-α agents to MS patients has been associated with increased disease activity. Insomuch as TNFR1 mediates demyelination and TNFR2 remyelination, it could be hypothesized that anti-TNF-α agents which selectively inhibit sTNF or signals from TNFR1 could be effective in treating MS.
|
Authors | Ana Caminero, Manuel Comabella, Xavier Montalban |
Journal | Journal of neuroimmunology
(J Neuroimmunol)
Vol. 234
Issue 1-2
Pg. 1-6
(May 2011)
ISSN: 1872-8421 [Electronic] Netherlands |
PMID | 21474190
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2011 Elsevier B.V. All rights reserved. |
Chemical References |
- Antibodies
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Tumor Necrosis Factor-alpha
|
Topics |
- Animals
- Antibodies
(therapeutic use)
- Disease Models, Animal
- Humans
- Models, Biological
- Multiple Sclerosis
(therapy)
- Receptors, Tumor Necrosis Factor, Type I
(metabolism)
- Receptors, Tumor Necrosis Factor, Type II
(metabolism)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, immunology, metabolism)
|